- ISIN
- US44486Q1031
- CUSIP
- 44486Q103
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Aug 26, 2021
Highlights
- Market Cap
- $109.77M
- Enterprise Value
- $129.56M
- EPS (TTM)
- -$0.57
- Total Revenue (TTM)
- $2.02M
- Gross Profit (TTM)
- -$13.55M
- EBITDA (TTM)
- -$173.00M
- Year Range
- $0.55 - $2.76
- Target Price
- $3.00
- ROA (TTM)
- -88.27%
- ROE (TTM)
- -839.56%
- Avg. Volume (1M)
- 6M
- Avg. Volume Value (1M)
- $4.45M
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
HUMA Performance Chart
Humacyte, Inc. (HUMA) is down 32.0% since the beginning of the year. At $1 per share, HUMA is trading 76.3% below its 52-week high of $3.
Loading charts...
Compare this symbol against anything
Returns By Period
Humacyte, Inc. (HUMA) has returned -31.97% so far this year and -71.34% over the past 12 months.
Humacyte, Inc.
- 1D
- -2.71%
- 1M
- -7.97%
- 6M
- -34.51%
- YTD
- -31.97%
- 1Y
- -71.34%
- 3Y*
- -41.18%
- 5Y*
- —
- 10Y*
- —
- ALL TIME*
- -42.74%
Benchmark (S&P 500 Index)
- 1D
- 0.70%
- 1M
- 0.09%
- 6M
- 7.94%
- YTD
- 9.41%
- 1Y
- 20.07%
- 3Y*
- 17.84%
- 5Y*
- 11.25%
- 10Y*
- 13.26%
- ALL TIME*
- 8.09%
HUMA Monthly Returns History
Based on dividend-adjusted daily data since Aug 26, 2021, HUMA's average daily return is -0.03%, while the average monthly return is -0.06%.
Historically, 50% of months were positive and 50% were negative. The best month was Jul 2024 with a return of +97.1%, while the worst month was Mar 2025 at -49.9%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 4 months.
On a daily basis, HUMA closed higher 45% of trading days. The best single day was Dec 20, 2024 with a return of +34.1%, while the worst single day was Oct 7, 2025 at -33.7%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 3.87% | 11.76% | -45.59% | 38.75% | 54.43% | -39.97% | -16.27% | -31.97% | |||||
| 2025 | -9.31% | -25.76% | -49.85% | -14.96% | 84.14% | -21.72% | 14.83% | -35.42% | 12.26% | -4.02% | -19.16% | -28.85% | -80.98% |
| 2024 | 16.90% | 31.02% | -28.51% | 26.05% | 90.82% | -35.83% | 97.08% | -36.05% | -10.08% | -7.17% | -10.50% | 11.73% | 77.82% |
| 2023 | 24.64% | 16.35% | 0.98% | 4.85% | 5.86% | -16.62% | 14.69% | 16.77% | -23.50% | -27.65% | 25.00% | 7.17% | 34.60% |
| 2022 | -25.79% | 12.08% | 17.08% | 0.28% | -23.31% | -40.88% | 8.41% | 4.89% | -10.68% | 5.67% | -9.43% | -32.37% | -70.90% |
| 2021 | 43.33% | -20.59% | -21.62% | 19.01% | -33.06% | -28.92% |
Benchmark Metrics
Humacyte, Inc. has an annualized alpha of -24.99%, beta of 1.76, and R2 of 0.09 versus S&P 500 Index. Calculated based on daily prices since August 26, 2021.
- This stock participated in 242.55% of S&P 500 Index downside but only 80.93% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.09 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -24.99%
- Beta
- 1.76
- R²
- 0.09
- Upside Capture
- 80.93%
- Downside Capture
- 242.55%
Return for Risk
Risk / Return Rank
HUMA ranks 13 for risk / return — above 13% of stocks peers on PortfoliosLab. Its historical combined result is below most peers; review the five component ranks for context.
Risk / Return Metrics
The table below present risk-adjusted performance metrics for Humacyte, Inc. (HUMA) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| HUMA | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -2.05 | ||
| Sortino ratioReturn per unit of downside risk | -2.75 | ||
| Omega ratioGain probability vs. loss probability | 0.91 | 1.25 | -0.35 |
| Calmar ratioReturn relative to maximum drawdown | -0.95 | 2.00 | -2.95 |
| Martin ratioReturn relative to average drawdown | -1.34 | 8.49 | -9.83 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Humacyte, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Humacyte, Inc. was 96.62%, occurring on Mar 30, 2026. The portfolio has not yet recovered.
The current Humacyte, Inc. drawdown is 96.15%.
Drawdown | Fall | Recovery | Underwater | Related event |
|---|---|---|---|---|
-96.62%Mar 2026 | 4y 7mo | — | 4y 11moSep 2021 - now | — |
Drawdown Indicators
| HUMA | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -96.62% | -56.78% | -39.84% |
Max Drawdown (1Y)Largest decline over 1 year | -76.83% | -9.10% | -67.73% |
Max Drawdown (3Y)Largest decline over 3 years | -93.93% | -18.90% | -75.03% |
Max Drawdown (5Y)Largest decline over 5 years | — | -25.43% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -96.15% | -1.58% | -94.57% |
Average DrawdownAverage peak-to-trough decline | -76.82% | -10.70% | -66.12% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 54.37% | 2.14% | +52.23% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Humacyte, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Humacyte, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for HUMA relative to other companies in the Biotechnology industry. Currently, HUMA has a P/S ratio of 55.6. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for HUMA in comparison with other companies in the Biotechnology industry. Currently, HUMA has a P/B value of 11.1. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with HUMA
Add Humacyte, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with HUMA